Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Safety and Effects of NTRX-07 for Patients with Mild Cognitive Impairment or Mild to Moderate Alzheimer's Disease

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a new treatment called NTRX-07 for individuals with Mild Cognitive Impairment (MCI) or Mild to Moderate Alzheimer's Disease (AD). Alzheimer's Disease is a condition that affects memory and thinking skills, and Mild Cognitive Impairment is an early stage of memory loss or other cognitive ability loss. The study aims to evaluate the safety and how well people tolerate the treatment when taken for 28 days.

Participants in the study will receive either the active drug NTRX-07 or a placebo, which looks like the active drug but does not contain the active substance. The study is designed to be "double-masked," meaning neither the participants nor the researchers will know who is receiving the active drug or the placebo during the trial. This helps ensure that the results are not influenced by expectations about the treatment.

The trial will also look at how the body processes NTRX-07 by studying its presence in the blood and cerebrospinal fluid, which is the fluid surrounding the brain and spinal cord. The study will last for a total of 28 days, during which participants will be closely monitored for any side effects or changes in their condition. The goal is to gather information that could help in developing effective treatments for Alzheimer's Disease and Mild Cognitive Impairment in the future.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying age, weight, and health status.

    Participants must be between 65-80 years old, with a body weight of 55-110 kg and a body mass index (BMI) between 18-35 kg/m².

  2. Step 2

    Baseline evaluation

    A baseline evaluation is performed to assess cognitive function and confirm the diagnosis of mild cognitive impairment (MCI) or mild to moderate Alzheimer's disease (AD).

    This includes tests such as the Clinical Dementia Rating (CDR) and the Mini-Mental State Examination (MMSE).

  3. Step 3

    Medication administration

    Participants receive the study medication, NTRX-07, or a placebo. The medication is administered orally in the form of a tablet.

    The dosage is 45 mg per tablet, taken once daily for a duration of 28 days.

  4. Step 4

    Monitoring and follow-up

    Throughout the 28-day period, participants are monitored for any adverse effects and changes in health status.

    Regular follow-up visits are scheduled to assess the safety and tolerability of the medication.

  5. Step 5

    Final assessment

    At the end of the 28-day period, a final assessment is conducted to evaluate the overall effects of the medication.

    This includes measuring plasma and cerebrospinal fluid (CSF) levels to understand how the body processes the medication.

Who can join the trial?

12 criteria

  • Participants must be between 65 and 80 years old when they sign the consent form.
  • Body weight should be between 55 and 110 kg, and body mass index (BMI) should be between 18 and 35. BMI is a measure of body fat based on height and weight.
  • Male participants must agree to either not have heterosexual intercourse or use a condom during intercourse for at least 90 days after the last dose of the study drug. They should also be aware that their female partner should use a highly effective birth control method.
  • Female participants must be unable to have children, either because they are at least two years past menopause or have been surgically sterilized.
  • Participants should have a Clinical Dementia Rating (CDR) between 0.5 and 2.0. This is a scale used to measure the severity of dementia symptoms. They should also have memory scores that match mild cognitive impairment or mild to moderate Alzheimer's Disease.
  • Participants must have a pTau 217 test result that matches Alzheimer's Disease or a recent amyloid test within the last two years. These tests help confirm Alzheimer's Disease.
  • If participants were in a previous study involving amyloid-directed treatments, they must have a negative ARIA report. ARIA is a type of brain scan result.
  • Participants should have medical records showing Alzheimer's Disease symptoms started at age 60 or later.
  • Participants should not have active depression and should have a Geriatric Depression Score of less than 6. This score helps measure depression in older adults.
  • Participants should not have changed their use of certain Alzheimer's medications, like acetylcholinesterase inhibitors or memantine, in the past six months and should not plan to start these medications during the study.
  • Participants must live at home with a reliable caregiver who sees them at least three times a week for 10 hours or more and can help with taking the study drug.
  • Participants and their caregivers must provide written consent, showing they agree to participate in the study.

Who cannot join the trial?

7 criteria

  • Patients with any other serious health condition that could interfere with the study.
  • Patients who are currently participating in another clinical trial.
  • Patients who have had a recent major surgery or are planning to have surgery during the study period.
  • Patients with a history of drug or alcohol abuse.
  • Patients who are pregnant or breastfeeding.
  • Patients who have an allergy to the study medication or its ingredients.
  • Patients who are unable to comply with the study procedures or follow-up visits.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

NTRX-07 is a medication being studied for its effects on people with mild cognitive impairment or mild to moderate Alzheimer's disease. The trial aims to understand how safe and tolerable this medication is when taken over a period of 28 days. Researchers are looking at how the body processes the medication and how it affects the symptoms of Alzheimer's disease.

What is already known about the treatment

NTRX-07 – This medication is administered orally and is currently being studied in clinical trials for its effects on mild cognitive impairment and mild to moderate Alzheimer's disease. It is in the investigational stage, with ongoing research to evaluate its safety and tolerability. The main therapeutic indication is to potentially improve cognitive function in affected individuals. NTRX-07 works by targeting specific pathways in the brain to reduce inflammation and support neuronal health. It is classified as a neuroprotective agent, aiming to slow down the progression of cognitive decline.

Investigated diseases

  • Mild Cognitive Impairment (MCI)

    MCI is a condition characterized by noticeable changes in cognitive abilities, such as memory and thinking skills, that are greater than expected for a person's age but not severe enough to interfere significantly with daily life. Individuals with MCI may experience forgetfulness, difficulty in finding words, or challenges in planning and decision-making. The condition can remain stable, improve, or progress to more serious cognitive disorders over time.

  • Mild to Moderate Alzheimer’s Disease (AD)

    Alzheimer’s Disease is a progressive neurological disorder that leads to memory loss, cognitive decline, and changes in behavior. In its mild to moderate stages, individuals may have trouble remembering recent events, managing finances, or performing complex tasks. As the disease progresses, difficulties in language, reasoning, and sensory processing become more pronounced, impacting daily activities and independence.

Trial detailsLast updated 2 Oct 2026
Age65+ yearsPhasePhase IITrial ID2024-517957-29-00Protocol codeNTRX-07-C201Estimated enrolment48 patientsSponsorNeurotherapia Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).